RCKY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RCKY is not a good buy right now for an impatient investor. Despite a constructive longer-term moving-average setup, near-term momentum is weakening (negative/expanding MACD histogram) and the stock is sitting right on key support (~31.48). With no Intellectia buy signals today and a notable increase in insider selling (+104% last month), the risk/reward favors waiting rather than buying immediately.
Trend/Momentum: The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which supports an underlying uptrend, but momentum has turned down: MACD histogram is -0.107 and negatively expanding (bearish near-term). RSI_6 at 38.8 is neutral-to-weak (not deeply oversold), suggesting downside pressure can persist.
Levels: Current price 31.45 is below the pivot (32.721) and essentially at S1 (31.475). A clean hold and rebound from ~31.48 could produce a bounce toward 32.72 then 33.97 (R1), but a breakdown increases risk toward S2 (30.706).
Statistical pattern read: Similar-pattern projection implies mild upside next day (+1.46%) but weakness over the next week (-1.38%), then modest upside over a month (+1.47%). Net: near-term choppy-to-weak, not an ideal immediate entry.
Intellectia Proprietary Trading Signals
showed solid fundamental momentum: revenue +6.97% YoY, net income +36.62% YoY, EPS +37.14% YoY, and gross margin improved to 40.21 (+5.54% YoY).
supports the broader trend.
fails, the next technical magnet is S2 ~30.71.
2025/Q3: Revenue increased to $122.54M (+6.97% YoY). Net income rose to $7.212M (+36.62% YoY). EPS improved to $0.96 (+37.14% YoY). Gross margin expanded to 40.21% (+5.54% YoY). Overall: profitable growth with meaningful margin expansion, which is a clear positive trend.
No analyst rating or price target change data was provided, so a recent Wall Street upgrades/downgrades trend and pros/cons consensus view cannot be assessed from the dataset. (From available info: fundamentals are improving, but near-term technicals and insider selling are the main current negatives.)
